



Press Release
Deferoxamine Mesylate for Injection, USP

Contact:

Grace Shen
Director of Marketing
888 729 9991

SICOR Introduces Deferoxamine Mesylate for Injection, USP

Irvine, California, March 31, 2006 — SICOR Pharmaceuticals Sales, Inc. is pleased to announce the introduction and availability of Deferoxamine Mesylate for Injection, USP. This product is AP rated to Desferal®*. Deferoxamine Mesylate for Injection is available in 500 mg/vial and 2 gm/vial, single dose glass vials.

“SICOR Pharmaceuticals continues to work toward improving access to affordable products,” states Michael Burton, Vice President, Sales and Marketing. “With the launch of Deferoxamine Mesylate for Injection, we offer our customers another cost-effective product.”

SICOR Pharmaceuticals Sales, Inc., a wholly owned subsidiary of TEVA Pharmaceuticals USA, is a leader in the development and marketing of specialty generic injectables. The company manufactures active pharmaceutical ingredients, finished dosage products and biopharmaceuticals.

*Desferal® is a registered trademark of Novartis Corporation.
Please see accompanying prescribing information.

Sicor Pharmaceuticals Sales, Inc.

A subsidiary of TEVA Pharmaceuticals USA

19 Hughes • Irvine, CA 92618-1902 • Toll Free: 800.729.9991 • Fax: 949.855.8210
Visit us at www.sicor.com